Avadel Cns Drug Patent Portfolio

Avadel Cns owns 1 orange book drug protected by 19 US patents Given below is the list of Avadel Cns's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11779557 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 16 Mar, 2042
Active
US11583510 Methods of administering gamma hydroxybutyrate formulations after a high-fat meal 07 Feb, 2042
Active
US10925844 Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state 28 Feb, 2040
Active
US10272062 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US10736866 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US10952986 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US10973795 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11000498 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11052061 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11065224 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11400065 Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state 21 Jul, 2037
Active
US11504347 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11602512 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11602513 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11766418 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11826335 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11839597 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11896572 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active
US11986451 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
Active


Given below is the list of recent legal activities going on the following drug patents of Avadel Cns.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 05 May, 2024 US10973795
Payment of Maintenance Fee, 4th Year, Large Entity 03 Apr, 2024 US10952986
Payment of Maintenance Fee, 4th Year, Large Entity 18 Mar, 2024 US10925844
Patent eGrant Notification 13 Feb, 2024 US11896572
Recordation of Patent Grant Mailed 13 Feb, 2024 US11896572
Email Notification 13 Feb, 2024 US11896572
Mail Patent eGrant Notification 13 Feb, 2024 US11896572
Patent Issue Date Used in PTA Calculation 13 Feb, 2024 US11896572
Recordation of Patent eGrant 13 Feb, 2024 US11896572
Payment of Maintenance Fee, 4th Year, Large Entity 02 Feb, 2024 US10736866 (Litigated)
Email Notification 25 Jan, 2024 US11896572
Issue Notification Mailed 24 Jan, 2024 US11896572
Application Is Considered Ready for Issue 02 Jan, 2024 US11896572
Dispatch to FDC 02 Jan, 2024 US11896572
Email Notification 12 Dec, 2023 US11839597


Avadel Cns's Family Patents


Family Patents



Avadel Cns Drug List

Given below is the complete list of Avadel Cns's drugs and the patents protecting them.


1. Lumryz

Lumryz is protected by 19 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11779557 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 16 Mar, 2042
(17 years from now)
Active
US11583510 Methods of administering gamma hydroxybutyrate formulations after a high-fat meal 07 Feb, 2042
(17 years from now)
Active
US10925844 Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state 28 Feb, 2040
(15 years from now)
Active
US10272062 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US10736866 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US10952986 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US10973795 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11000498 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11052061 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11065224 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11400065 Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state 21 Jul, 2037
(12 years from now)
Active
US11504347 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11602512 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11602513 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11766418 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11826335 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11839597 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11896572 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active
US11986451 Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics 21 Jul, 2037
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumryz's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List